Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

ss applicable to common stock of $2.7 million, or ($0.17) per share, basic and diluted, compared with a net loss of $3.7 million or ($0.29) per share for the same period in 2011. For the full year 2012, the Company reported a net loss applicable to common stock of $10.9 million, or ($0.72) per share, basic and diluted, compared with a net loss of $12.7 million, or $(1.06) per share in 2011. The full year 2012 results include $0.2 million of other income as well as $1.2 million of non-cash expense related to dividends and accretion on the preferred stock compared with $1.8 million in 2011. The weighted average number of shares used to calculate loss per share increased for the 2012 periods compared to the 2011 periods due primarily to the March 2012 offering of 2.7 million common shares as well as the payment of dividends in common stock.

Research and development expense for the fourth quarter of 2012 was $1.0 million, compared with $0.9 million for the same period in 2011. Research and development expense for the full year 2012, was $4.5 million, compared with $3.6 million in 2011. The increase for the fourth quarter and the year-over-year expenses is due primarily to increased pre-clinical activity in our fibrosis program as we prepared to file an IND in January 2013 and begin a Phase I clinical trial, offset by decreased expenses related to stock-based compensation.General and administrative expense for the fourth quarter of 2012 was $1.4 million, compared with $2.5 million for the same period in 2011. General and administrative expense for the full year 2012 was $5.4 million as compared to $6.9 million for 2011. The decrease for the fourth quarter and full year 2012 is due primarily to the recognition of a $1.0 million payment related to a separation agreement during the fourth quarter of 2011. Additionally, the decrease in expense for the fourth quarter and full year 2012 is due primarily to overall decreased business development costs as we decreased wor
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... Calif. , March 30, 2015  NuGene ... its subsidiary corporation, NuGene BioPharma, Inc. has added ... Dr. Guan is an internationally recognized ... finishing his college education at Peking University, ... Ph.D. degree from the University of North Carolina, ...
(Date:3/30/2015)... CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), ... commercialization of innovative therapeutics addressing cancer and other unmet ... focus on China , announced today ... approved the Company,s application to conduct a Phase 2 ... patients for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... , March 30, 2015  Spherix Incorporated (Nasdaq: ... to the fostering and monetization of intellectual property, ...  Case No. 3:13-cv-03494-M and  Spherix v. Uniden , ... District Court for the Northern District of ... Spherix v. Verizon, Case No. 1:14-cv-00721-GBL-TCB, ...
(Date:3/30/2015)... March 30, 2015  Naldemedine, an investigational peripherally ... Shionogi & Co., Ltd., met its primary and ... I) for the treatment of opioid-induced constipation (OIC) ... opioid therapy. Study results showed that naldemedine (0.2 ... the frequency of spontaneous bowel movement (SBM) compared ...
Breaking Biology Technology:UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
... of Wisconsin's neighbors has reaffirmed its support for stem ... in Wisconsin. , ,Illinois Gov. Rod Blagojevich last week ... funds to support stem cell research. The announcement makes ... stem cell research after New Jersey, California and Connecticut. ...
... be like without a cold war and arms race? For ... security is the new battleground with a steady escalation of ... little iPods everyone is carrying around in their pockets. With ... too easily blows a hole below the waterline of many ...
... - A group of business and technology leaders ... million in pledged state funds for the Biomedical ... between academic researchers and private industry in southeastern Wisconsin. ... Committee by a margin of 15-1, and endorsed by ...
Cached Biology Technology:Illinois stem cell funding could aid issue's visibility 2Info Security: Taking a page from the 1950s 2Info Security: Taking a page from the 1950s 3Budget axe could cut SE Wisconsin tech alliance funding 2Budget axe could cut SE Wisconsin tech alliance funding 3
(Date:3/20/2015)... OXFORD, Conn. , March 20, 2015 ... "Company"), a biometric authentication company focused on the growing ... Wocket® smart wallet is one of the products featured ... today, March 20th at 11:00 PM EST on the ... travels to Las Vegas , site ...
(Date:3/18/2015)... SPRINGS, Florida , March 18, 2015 ... well as businesses, new revolutionary smart wallets and apps continue ... pace.  Companies currently entrenched in the mobile payment industry in ... Alibaba Group Holding Ltd. (NYSE: BABA ), Apple ... GOOG ) and Facebook Inc. (NASDAQ: FB ...
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation (OTCQX: ... exhibition for service robots ever held in ... place on May 11-13, 2015 at the Javits ... for the event include: Acorn Product Development; Axis ... Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya Systems ...
Breaking Biology News(10 mins):NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... female meerkats subject their subordinates to escalating aggression and ... as a result infertile, a new study finds. , ... of her pregnancy, the dominant female in a meerkat ... for an average of three weeks at a time. ...
... A multi-institutional team of researchers has found that people with ... the brain responsible for voluntary movement and these signals can ... computer and converted into actions -- enabling a paralyzed patient ... 2006 issue of Nature, the researchers present the first published ...
... who - 10 years ago - created the cloned ... of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference in Boston, ... the world's leading scientists will discuss a variety of ... that is being hailed as the next revolution in ...
Cached Biology News:Dominant meerkats render rivals infertile 2Brain-computer link lets paralyzed patients convert thoughts into actions 2Brain-computer link lets paralyzed patients convert thoughts into actions 3Brain-computer link lets paralyzed patients convert thoughts into actions 4Brain-computer link lets paralyzed patients convert thoughts into actions 5Ten years later, Dolly is still making headlines 2
Polyclonal Antibody to CLAN...
Goat polyclonal to MLH3 ( Abpromise for all tested applications). entrezGeneID: 27030 SwissProtID: Q9UHC1...
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Biotin anti-mouse Ly-49C/F/I/H...
Biology Products: